Serdal KORKMAZ, Didem EREN, Aslı KUM, Enes FIRAT, Merve ELMAAĞAÇ, Yücel TEKİN

Hyperpigmented mycosis fungoides: A case report

A sixty-six-years old male patient was evaluated in the dermatology outpatient clinic with extensive hyperpigmented macules and two tumoral lesions approximately three cm diameter around the umblicus. Antimycotic and corticosteroid treatment was administered. However, as the complaints increased, a diagnosis of mycosis fungoides was made as a result of a skin biopsy. Six cures of single- agent gemcitabine chemotherapy were administered by the hematology outpatient clinic and a complete response was obtained. A case of mycosis fungoides is presented to increase awareness of this rare disease.

PDF

___

1. Lauren C Pinter-Brown, Emmanuel C Besa. Cutaneus T-Cell Lymphoma. WebMD. 2011;3:236-9.
2. Hoppe RT, Wood GS, Abel EA. Mycosis Fungoides and Sezary Syndrome: Pathology, staging, and treatment. Curr Probl Cancer. 1990;1:293-5. 3. Sanjay Vinjamaram, Emmanuel C Besa. Lymphoma Non-Hodgins. WebMD 2011; 2:1-4.3.
4. Joseph M. Connors, Erick D, Francine M. Foss. Lymphoma of the Skin. Am Society Hematology. 2012;1:263-78.
5. Elder D, Elenitsas R, Jaworsky C, et al. Lever's histopathology of the skin. New York. Lippincott raven Press. 1996.
6. Zain T, Grinkemeyer MD. Mycosis fungoides: Cutaneous T eel/ Am f'am Physician. 1991;43:1703-7.
7. Kirsch IR, Watanabe R, O'Malley JT, et al. TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. Sci Transl Med. 2015;7:308158.
8. Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides. J Am Acad Dermatol. 2005;53:1053-63.
9. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110:1713-22.
10. Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States cutaneous lymphoma consortium, and the cutaneous lymphoma task force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011;29:2598-607.
11. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768-85.
12. Ahn CS, ALSayyah A, Sangueza OP. Mycosis fungoides: an updated review of clinicopathologic variants. Am J Dermatopathol. 2014;36:933-48.
13. Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28:4730-9.
14. Olsen EA, Rook AH, Zic J, et al. Sezary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lym phoma Consortium (USCLC). J A Acad Dermatol. 2011;64:352-404.
15. Kim EJ, Hess S, Richardson SK, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest. 2005;115:798-812.
16. Hanel W, Briski R, Ross CW, et al. A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome. Am J Hematol. 2016;91:E491-5.